Cytokinetics, Incorporated (CYTK) Earnings Call Transcript & Summary

August 6, 2020

NASDAQ US Health Care Biotechnology earnings 57 min

Earnings Call Speaker Segments

Diane Weiser

executive
#1

Good afternoon, and thank you for being with us on today's call. Robert Blum, who serves as our President and Chief Executive Officer, is going to start things off by walking through the quarter along with the progress we've made lately. After that, Fady Malik, our EVP of Research and Development, will share updates on important developments regarding omecamtiv mecarbil, the cardiac myosin activator we're developing through our collaboration with Amgen, as well as the expanded and accelerated development plan for CK-274, our next in class cardiac myosin inhibitor. Following that, Stuart Kupfer, our SVP and Chief Medical Officer, will give an update on recent progress involving CK-274 and REDWOOD-HCM, and also CK-274, our additional cardiac myosin inhibitor. Then Robert Wong, our VP and Chief Accounting Officer, will walk through an overview of the quarter; and Ching Jaw, our SVP and Chief Financial Officer, is going to talk about our updated financial guidance in light of recent corporate development activities, before Robert Blum offers concluding thoughts regarding the company's outlook and the key milestones we expect for the rest of the year. Please be aware that portions of the discussion that follows, including how we respond to questions, include statements relating to future events and performance instead of historical facts, and these constitute forward-looking statements. What we actually achieve could differ materially from what these forward-looking statements project. Further information about factors that might cause our actual results to differ materially from those in these forward-looking statements appears in our SEC filings. We assume no obligation to update any forward-looking statements after this call; and with that, I'll hand the call over to Robert.

Robert Blum

executive
#2

Thanks, Diane, and I appreciate all of you being with us today. Our second quarter was productive, and that momentum is carrying over into this third quarter. A number of you have joined calls about our licensing collaboration and royalty monetization transactions, as well as our Investor and Analyst Day event that took place last month. Since we provided plenty of details on those calls only a few weeks ago, we will do our best not to repeat ourselves too much today. Without question, this marks a genuinely transformative period in our company's maturation, and I take great pride in the strategic execution our leadership team has shown at such a high level. Through the licensing, royalty monetization, and equity capital market deals we completed, our projected cash balance sheet at year-end is strengthened to more than $500 million, and our strong financial position is assured as we get closer to top line results of GALACTIC-HF, one of the biggest Phase III global cardiovascular outcomes trials in heart failure, which Amgen is running under our long-standing collaboration. When we consider these deals together with the renegotiation of our Astellas agreement that we announced previously, we are able to keep up readiness and implementation activities tied to the potential commercialization of omecamtiv mecarbil, and at the same time plan for the advancement of CK-274 and reldesemtiv, all within the context of our Vision 2025. Beyond the chance to co-commercialize omecamtiv mecarbil alongside Amgen, these recent deals let us keep control over the development of CK-274 and reldesemtiv across an expanded set of pivotal clinical trials, while holding on to full rights in North America, Europe and Japan for our shareholders. It is especially satisfying when our R&D strategies can align with and support the corporate development and business development strategy. Cytokinetics keeps leveraging our innovative science through partnerships to maximize opportunities throughout the breadth and depth of our pipeline of investigational medicines focused on muscle biology. With that, I will hand the call to Fady to go into more detail on key developments for omecamtiv mecarbil and CK-274.

Fady Malik

executive
#3

Thank you, Robert. Despite the coronavirus pandemic, both we and Amgen achieved meaningful progress this quarter. As we've noted before, we're lucky regarding how GALACTIC-HF is being run, because the trial is already at such an advanced stage. Amgen modified how the study was carried out so that investigational product could be delivered to patients' homes, and so that study visits — including remote visits for endpoint data collection — could take place. Keep in mind that no primary endpoint of the trial, whether heart failure events, any death, or gathering of the Kansas City of Cardiomyopathy questionnaire week 24, requires patients to show up in person at clinical trial sites. Now, with the trial nearing completion, Amgen, working alongside Cytokinetics, keeps pushing diligently on close out activities. The trial is still blinded while final events accumulate, and we move toward final data collection and database lock. We anticipate accruing the last event shortly, wrapping up GALACTIC-HF in Q3, and we're still on schedule to report top line results for GALACTIC-HF in Q4. On METEORIC-HF, our second Phase III study of omecamtiv mecarbil in heart failure patients, I'm happy to report that although enrollment was suspended earlier this quarter because of the coronavirus pandemic, screening and enrollment restarted in June together with our clinical trial sites. Among the 9 countries taking part in METEORIC-HF, 4 are recruiting right now, and we anticipate the other 5 joining later in the third quarter. Roughly 75% of our target 92 sites are now activated across the United States, Canada, France, Germany, Italy, Hungary and the Netherlands. Recruitment has restarted, and we're extremely thankful to the personnel at our clinical trial sites for working with us to protect trial participants' health and safety throughout this study. As we've said, METEORIC-HF results don't sit on the critical path for submitting regulatory filings seeking potential approval of omecamtiv mecarbil. Rather, should METEORIC-HF findings prove supportive, they'd go into a supplemental filing after the potential commercial launch, which is predicated on expected GALACTIC-HF results; enrollment in METEORIC-HF is now expected to finish in early 2021. With heart failure's health economic burden growing globally, our enthusiasm for omecamtiv mecarbil's promise is unchanged. This potential medicine's novel mechanism of action operates completely differently from therapies available today and could become foundational to standard of care. Notably, this quarter the FDA awarded fast track designation to omecamtiv mecarbil, which might lead to an expedited review. We also worked with Amgen and Servier preparing a potential marketing application dossier for omecamtiv mecarbil, and got ready for possible meetings with regulatory authorities, should they be requested, to discuss Phase III trial results and potential marketing applications. Now let me turn to our cardiac myosin inhibitor program. This marks a thrilling moment for us as we grow and speed up this development initiative. As Robert noted, with respect to the licensing collaboration and royalty monetization agreements involving Ji Xing Pharmaceuticals and RTW Investments, those arrangements let us pursue CK-274 across several indications simultaneously and over a broader range of geographies. On the details of the development program tied to CK-274, these transactions give us backing to run a planned Phase III clinical trial of our next-in-class myosin inhibitor in obstructive HCM patients in North America, Europe, and, together with our partner, in China, right after we obtain results from REDWOOD-HCM and get feedback from regulatory authorities. Right now, we aim to kick off a Phase III registration program for CK-274 and obstructive HCM in late 2021, and we're collaborating with our new partner, Ji Xing, to make concurrent development possible in China; at the same time, we're preparing to conduct clinical trials of CK-274 in nonobstructive HCF — HCM and in a subgroup of heart failure patients with preserved ejection fraction, or HFpEF, also during the 2021 or 2022 time frame. In summary, the July deals strengthen our dedication to swiftly and extensively move our cardiac myosin inhibitor program forward, with the hope of potentially delivering the next-in-class medicine capable of meaningfully addressing the underlying difficulties faced by patients dealing with hypertrophic cardiomyopathies and HFpEF related to the hypercontractility of cardiac muscle. Now I'll hand things over to Stuart for an update on REDWOOD-HCM along with our plans for the Phase I study of CK-271, our second cardiac myosin inhibitor.

Stuart Kupfer

executive
#4

Thanks, Fady. I have good news to share: after enrollment was paused for a short time because of the coronavirus pandemic, we restarted screening and patient enrollment in REDWOOD-HCM during the second quarter, working alongside our CRO and the partners at our clinical trial sites. As everyone knows, REDWOOD-HCM is the Phase II study of CK-274 in obstructive HCM. We brought many sites online in the second quarter, and by the close of Q3 we expect roughly 25 out of the 27 total sites to be activated and enrolling patients across the U.S. and Europe. Lately, screening and enrollment have picked up, and we are happy that all the preparatory work done quietly while the trial was briefly halted is now delivering results. Even while no enrollment was taking place, site activation continued, patients were identified, and screening visits got scheduled thanks to coordination between our CROs and the sites. Today we see new centers bringing patients in, and certain sites have more than one patient waiting in the screening queue; our plan is to enroll 18 patients in the first cohort, and we anticipate having data that will guide whether we move to Cohort 2 by the end of this year. This quarter, we and others were delighted that EXPLORER, our Phase III clinical trial, produced positive results, which offers encouraging validation for how cardiac myosin inhibition works in patients with obstructive HCM and gives us optimism about a potentially impactful new therapy for these patients. Being diligent students of clinical development, we have a chance to take what EXPLORER taught us and apply it to our own clinical development program, pushing the field forward as we advance CK-274 in obstructive and non-obstructive HCM, plus in a subgroup of HFpEF patients with hypercontractility of cardiac muscle. With the potential advantages CK-274 offers as a next-in-class therapy, we have an opportunity to do better than the safety and efficacy profile seen in EXPLORER. Now on to our other cardiac myosin inhibitor, CK-271. After the recent setback caused by a resurgence of coronavirus cases near our Phase I site, our plan now is to start screening in the first cohort during this quarter. As a reminder, the main goal of this first-in-human Phase I study is evaluating safety and tolerability along with the pharmacokinetics of single ascending oral doses of CK-271 in healthy adult subjects. Lastly, Cytokinetics was glad to support the patient-focused drug development meeting for HCM patients hosted by the HCMA. That important meeting highlighted the tremendous burden of disease and the daily challenges patients face. Without question, the unmet need for new therapies to treat hypertrophic cardiomyopathy is substantial, and we commend the HCMA for bringing this issue to the forefront. With that, I'll hand things over to Robert Wong, who will give an update on our financials.

Robert Wong

executive
#5

Thanks, Stuart. To start, I'll cover where we stand on cash, revenue, and spending, and after that Ching will walk through how we're advancing our corporate development strategies. You can find further specifics about our actual second-quarter results in the press release that went out earlier this afternoon. We closed out the second quarter with roughly $213 million in cash and investments. Revenue during Q2 2020 was generated through our strategic alliances with Amgen and Astellas; with Amgen, we recorded revenue tied to their reimbursement of our development costs for METEORIC-HF. With Astellas, we recorded revenue for their reimbursement of costs tied to our scientists working on collaborative research. R&D expenses for the second quarter of 2020 fell to $21.8 million, down from $24.0 million during the same period in 2019, largely because of reduced spending on our neuromuscular development work following completion of FORTITUDE-ALS in 2019, partly offset by greater activity tied to REDWOOD-HCM in 2020. Over 50% of our R&D expenses stemmed from our cardiovascular programs, as anticipated given the activity for METEORIC-HF and the cardiac myosin inhibitor program, while the rest of our expenses stemmed mainly from our early research work. G&A expenses for the second quarter of 2020 totaled $14.2 million, rising from $9.8 million in Q2 2019, mostly because of greater personnel-related costs, among them stock-based compensation, along with higher outside services for pre-commercial activity; and at this point Ching will go over progress related to corporate development strategy.

Ching Jaw

executive
#6

Robert, appreciate that. As we've discussed previously, over the past twelve months we've worked alongside both our leadership group and our Board, ensuring a strong financial footing while the company moves toward becoming a completely integrated biopharmaceutical entity. Our recent transactions involving business development, royalty monetization, and an equity offering have put us in a solid financial spot to get the fund up and running — meaning we can operationalize and finance projects and initiatives across the near and midterm horizon. Looking back at where our cash stands: the second quarter closed out with $213 million, and once this mavacamten royalty monetization wraps up we'll bring in another $160 million, along with $90 million more in capital that we can draw on at our discretion through the RTW deals. On top of that, our equity offering that took place recently brought in roughly $190 million after expenses were deducted. Our expectation is that 2020 will close out with over $500 million in cash, along with committed cash that depends on closing conditions being met. Financial guidance for 2020 was also refreshed by the company; cash revenue is still expected to land between $18 million and $22 million, while operating expenses should fall somewhere in the $120 million to $130 million range. That said, for projected full year net cash utilization, we've tightened the range to $110 million to $115 million. We won't provide official 2021 guidance until the Q4 earnings call. That said, we anticipate finishing this year with over $500 million on the balance sheet. We expect that amount to cover more than three years of forward cash, even while we grow the CK-274 development program and pursue co-promotion of omecamtiv mecarbil with Amgen. Should GALACTIC-HF produce positive results in Q4, milestone payments could come through within the next 12 to 18 months. Additionally, once commercialization occurs, royalties on tier worldwide sales of omecamtiv mecarbil outside Japan might surpass 20%, with a reduced royalty rate in Japan. The deals we just closed give us additional ways to make use of our Amgen alliance as we grow the commercial side of the business. At the same time, we now have funding available to grow our biopharmaceutical research platform, aiming to double our development pipeline in size within the coming 5 years, which is what we laid out in Vision 2025. Having said that, I'll hand things back to Robert Blum.

Robert Blum

executive
#7

Thank you, Ching. This was truly a strong quarter, and the momentum keeps building as we head into the back half of this year. Building on what Ching said earlier about possibly commercializing omecamtiv mecarbil, Amgen and Cytokinetics plan to draw on what each company does best in order to inform the heart failure community about the drug's potential clinical effects and its economics, as well as where it could fit within the continuum of care. Working alongside Amgen on co-promotion, our plan is a coordinated field deployment strategy that uses a reach and frequency approach across institutional accounts in North America. Along those lines, we recently carried out analyses focused on the U.S. heart failure institutional care market segment, which covered assessing and prioritizing potential target accounts for the commercialization we have planned. In addition, we keep running commercial readiness work together with Amgen as we get ready to commercialize omecamtiv mecarbil, which includes market research on product branding elements, possible positioning, physician preferences, and prospective customer accounts. Last, we carried on collaborating with providers and healthcare systems to produce health economics and outcomes research tied to the healthcare costs of treating heart failure patients. On the heart failure education side, as we mentioned at our recent Investor and Analyst Day, we launched a disease state education program aimed at teaching the heart failure community about the unmet needs of heart failure patients and explaining how contractility drives cardiac performance in HFrEF. Importantly, the commercial operations we are constructing to support omecamtiv mecarbil, funded in large part by Amgen, can be used to commercialize CK-274 should it succeed in North America and Europe. On top of that, our recent transactions with RTW and Ji Xing Pharmaceuticals speed up our development programs and widen our geographic reach, while keeping open the chance to leverage further through possible additional partnerships. Last, on the neuromuscular front in the second quarter, we kept getting ready for reldesemtiv's potential move to a Phase III clinical trial in patients with ALS, and we spoke with clinical experts and patient advocates and assisted technology assessment organizations to obtain feedback on endpoints and other issues concerning the trial's design. We also got advice from EMA via protocol assistance for the Phase III trial. During the quarter as well, we announced that our long-standing partnership with the ALS Association in the fight against ALS will continue — more proof of our unwavering commitment to this brave and inspiring patient population. To sum up, Cytokinetics is well positioned to keep executing against our Vision 2025 as we head toward what we see as a transformative period in the company's maturation, leading into the close of this year and our expected GALACTIC-HF results in Q4. Let me now recap the milestones we expect for 2020. For omecamtiv mecarbil, we expect top line results from GALACTIC-HF in the fourth quarter, and we expect enrollment in METEORIC-HF in patients with heart failure to wrap up in early 2021. Regarding AMG 594, the Phase I trial for that compound has finished, and we're still analyzing the data. Amgen and Cytokinetics are currently talking about where the development program goes from here. Turning to CK-274, our goal is to finish enrolling the first cohort of REDWOOD-HCM and to have results that will guide whether the trial moves ahead into the second cohort before 2020 comes to a close. As for CK-271, we plan to launch a Phase I study during Q3 2020. With reldesemtiv, we intend to keep getting ready for a possible Phase III clinical trial and registration program involving ALS patients. On the research side, we plan to keep up our work focused on the cardiac and skeletal sarcomere along with our other muscle biology research programs. We also anticipate carrying on research alongside Astellas aimed at finding next-generation skeletal sarcomere muscle activators through 2020. Operator, that covers everything, so please go ahead and open the call for questions.

Dane Leone

analyst
#8

Questions. Let me kick things off, then. After the deal concerning 274, folks in the investment community have been sending us questions. From where you sit strategically, as you move 271 forward, how would you handle two assets sharing a similar MOA that are in the clinic simultaneously, and in what ways could they be distinguished by indication, assuming you've looked that far ahead? Then my second one would be whether you can share anything that sets expectations for the REDWOOD-HCM readout covering Cohort 1 before this year ends? Also, what's your thinking on the critical data points you'll review, the ones you'd also want investors watching closely?

Robert Blum

executive
#9

Sure. I'll begin, then hand things to Fady, and perhaps Fady will hand things to Stuart; there are 2 questions in what you asked. First, regarding 271. As has been our pattern at Cytokinetics, and you're only starting to learn about us, we have consistently moved forward lead compounds, backups, follow-ons, and diversified across both chemical and pharmacokinetic space for the mechanism of action we aim to take through clinical research. The reason we say clinical research is that, clearly, there's a chance to broaden and diversify. As for CK-274, we remain committed to, as you've heard, obstructive and non-obstructive, plus we're evaluating HFpEF; and when it comes to CK 271, the profile truly determines everything. What we discover about CK-274, and likewise about CK-271, might allow us to contemplate a wider development program. We're additionally moving other compounds ahead from that same program, with different mechanisms and different properties, so we could anticipate additional compounds reaching the clinic; I'll leave my part there and perhaps ask Fady to say more, and to take your second question about which data we'll examine at REDWOOD to guide the second cohort.

Fady Malik

executive
#10

Robert, my sense is that you've already addressed that initial question. Regarding 271, my understanding is that those results emerged from its Phase I study. Then, once additional findings for 274 become available, we'll start shaping our approach around those 2 medicines. On the REDWOOD-HCM front, perhaps I should hand things to Stuart, since he has been monitoring that trial's advancement quite closely; he can walk us through what we plan to do as the year winds down, covering both the data and where we go next.

Stuart Kupfer

executive
#11

Right, thanks Fady. As we said, we're aiming to have Cohort 1 data ready before the year is out. Really, this trial's primary goal is safety and tolerability, so those safety endpoints will get most of our attention. That said, from a strategic standpoint, our big focus is on the individualized dosing approach we built into how the study is designed. Because the population we're enrolling will cover a pretty wide spectrum of disease severity, we expect that doses could differ from one patient to the next, based on each person's pathophysiology or how severe their condition is. On the pharmacodynamic side, though, we'll be assessing improvement in the left ventricular outflow tract gradient, which in this population plays a major role in heart failure symptoms and poor cardiac function, and we'll also look at signs and symptoms plus other pharmacodynamic endpoints such as NT-proBNP. So when we put all the study data together, it will tell us about the range of doses being tested in cohort one. Those findings will then guide moving forward into a higher dose range, which is what we have planned for Cohort 2.

Dane Leone

analyst
#12

Thanks. I just need one point of clarity regarding my earlier question — apologies for that. What investors are attempting to figure out, I believe, is if any legal barrier existed under the RTW agreement that stopped 271 from being created for those same indications. Sorry, I simply wanted to get that clarified.

Robert Blum

executive
#13

Apologies — nothing contained in the contract we signed blocks our capacity to advance CK-271 however we choose. Therefore, at this moment we have no plans to do so. As of now, CK-271 must still go through characterization in Phase I, and CK-274 likewise in Phase II. Thus, our aim is to push several compounds ahead, as I stated, and we will gain knowledge regarding these compounds' physiochemical properties and other aspects so that we can stay at the forefront in this area spanning various indication types, various patient subtype categories, and so forth. So, regarding what you asked, no, nothing stands in our way.

Jeff Hung

analyst
#14

So you said AMG 594's Phase I is finished. When could data from that reach us? And do you think you'll advance in just a single indication? Or will it probably be pursued in parallel across several indications, the way CK-274 is? Then I've got one more thing to ask.

Robert Blum

executive
#15

That's a really good question. At this moment, we're in the middle of getting those data, assessing them, and running analyses — and honestly, that effort has only just gotten underway. On the Phase II side, indication-wise, our thinking is broad. We've had an exercise going that brings in market research, plus collaboration with key opinion leaders, clinical assessments, trial design, endpoint evaluation — everything of that sort that could shape a broad development program spanning potentially many different indications, since as a cardiac muscle activator there are lots of paths open to us, covering both big market opportunities and what you might call more specialized care segments. So with Amgen, that's what we're considering, and we'll likely be able to say more on all of it later in the year. Until then, though, it remains at the paper and pencil exercise stage.

Jeff Hung

analyst
#16

So then, taking "later this year" as your timing, is that the point at which portions of the Phase I data could become visible to us? Or…

Robert Blum

executive
#17

Right. My expectation is that once particular choices get made, we'll be able to disclose results that may back up those choices.

Jeff Hung

analyst
#18

All right, that’s helpful. And building on what was just asked, I understand that CK-271 still has to be characterized in humans. So could you perhaps discuss how the preclinical profile of CK-271 differs from that of CK-274?

Robert Blum

executive
#19

Fady, would you like to address that?

Fady Malik

executive
#20

Sure, I can handle that question. So, looking at the preclinical data, CK-274 and 271 work through comparable pathways. The main distinctions lie slightly in how sharp the exposure-response curve is for each of the 2 compounds, and their pharmacokinetic profiles differ somewhat in preclinical studies too. That's why we moved it forward — to introduce some variability in PK and PK/PD when we get into human trials, and leverage that to guide how we push this mechanism of action ahead in patients, plus it gives us a chance to divide up indications or explore other possibilities you might consider.

Robert Blum

executive
#21

It seems Jason may have dropped off. Perhaps we can put him back in line and move on to whoever's next.

Charles Duncan

analyst
#22

Robert and the rest of the team, forget COVID for a moment. You folks have achieved quite a bit. My congratulations. I had one brief thing about the timing for omecamtiv, and then something about strategy. So, starting with when omecamtiv will come, Fady did an excellent job describing essentially what to expect. Still, I'm sort of curious: if we assume GALACTIC succeeds, at what point do you think you could submit an NDA? Has all the CMC work been finished? Do you think it would be possible to hold a meeting — a pre-NDA meeting — with the agency prior to, let's say, the middle of the first quarter of next year?

Robert Blum

executive
#23

Fady, that one goes to you, and I'll add more after.

Fady Malik

executive
#24

Yes. Charles, my sense is that Amgen and Cytokinetics have spent the last 2 years getting ready quite vigorously for a possible NDA filing, so all of it has been sped up to make the gap between trial results and submitting an NDA as short as we can. So I believe you'd find that — the results back this up and the way ahead appears clear. I think you'd find us proceeding toward an NDA filing very soon, very quickly. I wouldn't really point to anything else — apart from the results — that we need to have in hand so that an NDA filing can move ahead.

Robert Blum

executive
#25

Yeah, and perhaps I can add a bit more detail. Those work streams, like Fady mentioned, have been underway for a good while now, and teams at both organizations are putting in serious effort to get the study reports ready and make sure everything goes through quality control — not only for what would be the U.S. filing, but for submissions outside the U.S. as well. I'd say that speaks well of how we've been collaborating, engaging very proactively across these work streams, since we recognize the importance of moving quickly so potential approvals can happen. As you're aware, the drug holds a fast track designation, and that might also help enable a quicker review timeline. So everything here lines up with what we expect — we need to be ready to co-commercialize as early as possible in 2021.

Charles Duncan

analyst
#26

All right, that's quite useful. Now, a brief question about the approach in Asia. I understand that you revised the partnership a few years back so that it covered Japan. However, I don't remember what the strategy is for other nations in Asia, like China. Could you give us some insight?

Robert Blum

executive
#27

Certainly. The alliance between us and Amgen operates on a global scale, and China falls within it. Japan used to be left out. Yet, as you pointed out, back in 2013, Japan was brought in. Thus, at this point it genuinely covers the entire world. And this isn't only between Amgen and Cytokinetics — with our approval, Amgen granted a sublicense to Servier covering Europe along with other Commonwealth independent states, which lets Servier be, if you'll excuse the wordplay, the muscle behind serving as a commercial partner in regions where their particular know-how lies. When it comes to co-commercialization, our part is a global one; it's a worldwide one. It reaches every country, and that falls under the commercialization oversight of a joint commercialization committee. As for co-promotion, our part is North American, and the place where our sales and marketing staff will concentrate is North America. Royalties come to us from sales across the globe. I hope that clarifies things.

Charles Duncan

analyst
#28

All right, that answers it. I enjoy a good play on words. One final thing for Ching. Ching, you were describing where cash will stand when this year closes. And I can't tell whether you made a slip of the tongue or I didn't catch it properly — probably the second one — that when '21 wraps up, you might also finish the year holding $500 million, and my guess is that figure factors in certain milestone payments and maybe royalty revenue too. Is that right? Or did I not hear it correctly?

Ching Jaw

executive
#29

No, Charles. But here's what reached my ears — what I actually stated is that 2020 will close with more than $500 million. Nothing was mentioned by me regarding 2021.

Charles Duncan

analyst
#30

All right, that makes sense. However, you brought up milestones and possibly royalties within the coming 12 to 18 months, right?

Ching Jaw

executive
#31

Yes, that's right; and that relates to omecamtiv mecarbil, should GALACTIC turn out positive.

Emanuela Branchetti

analyst
#32

Emanuela here, on behalf of Joe Pantginis. I've got a few questions. Could you provide additional detail regarding what came out of those analyses — the marketing work you're doing, plus your commercialization efforts? Specifically, I'm trying to figure out, among the heart failure population, which patient segment you'll pursue initially, and who will receive mavacamten first?

Robert Blum

executive
#33

Certainly. A moment will come when we're able to speak with greater precision and go deeper on this. Broadly speaking, though, here's what I can tell you: we're evaluating where Cytokinetics — an organization whose access to capital and resources is more constrained — can establish a commercial team capable of operating very effectively to grow the business, in institutional care segments characterized by high-volume heart failure. Certain of those accounts may be exclusive to Cytokinetics, while others could be ones that Amgen also shares. Even so, we're approaching this strategically. Where do we believe we can make the greatest impact on this opportunity when it comes to education, awareness, and pull-through — and where could those efforts also yield benefits and pay off later for us, tied to our interest in CK-274, where likewise there's a concentrated customer care segment with substantial overlap involving high-volume heart failure centers, and where those centers of excellence will handle the majority of HCM patients. So we're examining that intersection, so to speak, of heart failure and HCM as a way to guide our strategy — while acknowledging that additional work remains between Amgen and us to align and reach agreement on next steps concerning our co-promotion. That is something we're talking through with Amgen, aiming to achieve more granularity and clarity on all of it by the conclusion of this year.

Emanuela Branchetti

analyst
#34

Understood. Then, when it comes to Amgen — I noticed on clinicaltrials.gov that they've launched a post-trial access study, in which patients enrolled in GALACTIC-HF will receive the committee's access. That trial isn't active yet. Still, I wanted to know whether it's a follow-up, something like a longer-term follow-up trial. I'm curious, what's the goal of this longer term?

Robert Blum

executive
#35

Yeah, so that's an approach Fady will address and expand on when I hand it to him. Clearly, it hinges on results from GALACTIC, since those will be available in the fourth quarter?

Fady Malik

executive
#36

Yeah. Yeah. Some nations require, by law, that patients taking part in trials there keep getting the drug once the trial ends. So we're setting up a post-trial access program so those patients can be enrolled after finishing GALACTIC, provided the data back continued dosing. This isn't meant to cover the whole globe, in each and every country, but it will satisfy those places where the rule applies.

Edward Tenthoff

analyst
#37

I apologize for the background noise. Thank you, Ching, for the cardio update. I'd like to ask about reldesemtiv — can we get any news on that front? And what's the most recent on CK, regarding Astellas?

Robert Blum

executive
#38

My apologies, I had been on mute. That's a really good question. As we've said consistently in various communications, the situation is that we keep getting ready for a possible Phase III trial. As we noted, there were many activities in the second quarter acknowledging that, and I'm quite happy with what we're hearing back from both FDA and EMA, which lines up nicely with the trial design and endpoints we're contemplating. We met with HTAs in Europe to understand how they'd value those endpoints in connection with a possible trial. Everything here suggests that if we were to run a trial, the ALS community would respond positively to it; and from a practicality standpoint — design, time line and budget — we have a handle on it. But bearing in mind that we have not yet made a commitment to conduct the trial, as we've stated, that will depend on — looking at the GALACTIC results to truly grasp what our runway is, what our cost of capital is, what our capacity is to finish what we start; and that remains a trial we'd like to pursue if possible, taking everything into account, but one we haven't committed to at this point.

Dennis Ding

analyst
#39

Dennis Ding here, filling in for Salim. Nice work on everything you've accomplished. If I could, 2 questions. First one's about GALACTIC. Roughly 50% of GALACTIC patients have an ischemia history. My guess is the heart probably has less functional tissue. And even following revasc, it seems to me there'd be less functional tissue. So what data have you looked at that makes you confident you can demonstrate the same clinical benefit for that group? Then my second one concerns HCM in particular. What's your thinking on the opportunity in Europe, and how does the EMA view the Phase III endpoints? Is it something along the lines of Peak VO2, as the right endpoint?

Robert Blum

executive
#40

Sure. I think I'll have Fady address both of those, please.

Fady Malik

executive
#41

Absolutely. Regarding your initial question, the evidence supporting the impact on both ischemic and non-ischemic cardiomyopathy is derived from GALAC — it actually comes from COSMIC, in which you examine how omecamtiv mecarbil performs in those patient subgroups; and what you basically observed was highly comparable outcomes concerning the measures of cardiac function improvement, the shifts in volumes, and the shifts in NT-proBNP. Although there are potentially fewer muscle cells in individuals who have ischemic cardiomyopathy, just — you need to keep in mind, there is typically still a great deal of viable myocardium, myocardium that remains and hypertrophies and enlarges. And they are still able to boost their function in reaction to the draw on omecamtiv mecarbil. And we have observed that as well in earlier trials, specifically COSMIC. So I believe there is a rationale for anticipating benefit across both types of subgroups. Could you please repeat your second question?

Dennis Ding

analyst
#42

Yeah, absolutely. So regarding the HCM opportunity over in Europe — how are you approaching that with respect to Phase III? And what's the EMA's stance on Phase III endpoints — would something such as Peak VO2 qualify as a legitimate endpoint?

Fady Malik

executive
#43

That's a fair question. From our side, it remains a little premature to say what the EMA might conclude regarding endpoints for Phase III. We've made initial contact with them, and over the next few months we intend to engage with them more thoroughly. Our plan for Phase III is to run it across both Europe and the U.S. There is definitely guidance originating from Europe concerning functional improvements in patients who have heart failure, or who have HCM, or certainly endpoints that are approvable. And perhaps it comes down to how one characterizes function or symptoms; and at this moment, I'd say we're still at the stage of figuring out what their vision is, or what their views on that happen to be.

Chad Messer

analyst
#44

Nice work on everything that's happened lately. Honestly, considering how long and how much work it took to reach this point, I'd have been thrilled simply to join a call that's 1 quarter out from omecamtiv data — but the fact that you're sitting in such a strong spot with the remainder of the pipeline heading into that is genuinely amazing.

Robert Blum

executive
#45

Chad, you've been following us for ages, so I'm sure it feels good to finally have this to talk about with you. And we're certainly eager for those results later in the year.

Chad Messer

analyst
#46

Thanks. Perhaps a broader question regarding your Vision 2025. One piece of that involves not simply halting at the programs discussed today, but continuing onward and having 10 drugs in development by that point, which, considering how prolific your drug discovery engine has proven, is ambitious yet definitely achievable. And I realize in your corporate deck, you mention expanding beyond your concentration on contractility into muscle energy and metabolism. A few weeks back, we found out you've been developing inhibitors of skeletal protein parasites, all of this, could you perhaps address some of those areas at a high level? And which sorts of conditions might be tackled by pursuing this new biology?

Robert Blum

executive
#47

That's an excellent question; and I'll begin, though it's preferable for you to hear Fady's perspective on it. We've adopted a strategy, and you've followed us for many years in this manner, in which we never aimed to become a business that would shift direction over a single new product or one indication. And it has required a very long period, clearly, for us to reach our current position. Yet simultaneously, we're empowered, financially as well as operationally, and with a pipeline, to construct, we trust, a highly sustainable and lasting enterprise that evolves alongside the science and keeps innovating and delivering new therapies; having said that, it matters to be self-aware and recognize where we believe a competitive edge is possible and where we can serve as leaders. And that's the space where we've broken new ground and remain at the forefront: contractility of muscle, which on its own has provided us an extremely wide pipeline, one that might extend considerably past even the indications we've discussed for the compounds currently in clinical trials. Reldesemtiv alone has the potential to constitute a pipeline by itself. And up to now, we've truly concentrated on, as you're aware, ALS and potentially SMA. But we likewise wish to ensure we're always attuned to the marketplace and to patients. And that's where we believe we've built a leadership standing concerning the biomechanics of muscle that also reaches into how muscle acts as a fulcrum in energetics growth and metabolism and additional indications, yet ought to stay inside our cardiovascular and neuromuscular vertical; so we will keep investing in pipeline, cardiovascular and neuromuscular; and since we spun out, as you observed, another company recently founded on discoveries we made, those will be more peripheral and more likely to be monetized through other means, so as to enable our leadership within these verticals. That being said, our thinking has to cover biology along with the marketplace, and that is precisely where Fady and the people working with him have assembled a solid road map as we extend past muscle contractility into mitochondrial biology. Perhaps he could share a few of those thoughts and ideas, since we are considering how we get from 5 products in development to as many as 10 development programs by 2025.

Fady Malik

executive
#48

Appreciate that, Robert. Chad, that's a really solid question; and like Robert mentioned, we've spent close to 20 years now exploiting sarcomere biology, building out a pipeline that includes cardiac muscle activators, cardiac muscle inhibitors, and skeletal muscle activators — and that pipeline is now reaching maturity in the clinic. There are definitely additional possibilities inside the sarcomere, and we'll keep capitalizing on our foremost know-how regarding that muscle structure. That said, we currently have quite a few programs in that space. And when we consider how to shift toward another key aspect of muscle — namely, the way muscle produces energy — your muscle is packed with mitochondria, which matter enormously for both heart health and skeletal muscle health. Of course, mitochondria aren't unique to muscle, though there are clearly muscle-specific uses of mitochondrial biology, and we're going to — we've actually been at this for some time already. Over the next few years, we'll start to see programs coming out of that area.

Robert Blum

executive
#49

Also, Chad, there's one more thing worth noting: we're going to keep doing what has always defined how we approach productivity, which is searching for those types of measurements we can see in preclinical work and pick up on pharmacodynamically in the clinic that are able to tell us something about function. We think that matters because it helps shape our understanding of what will end up being important for patients. When we consider function and performance, quality of life and health span, that's exactly where our muscle activators and our muscle inhibitors — these drug candidates — give us a read not just on morbidity and mortality, but on the things that will ultimately determine health span, particularly given how this relates to an aging population, and that's the space where we see our business continually changing.

Chad Messer

analyst
#50

Yeah. No, that sounds excellent. And it's genuinely encouraging to watch you all approach this with such a strategic mindset and to be sitting in a spot where you can map out multiple years of advancement. Incidentally, the notion of taking preclinical compounds and putting them into a freshly formed company that you nurture, receiving equity and royalties in return, feels eerily recognizable? I have a quiet hunch that this approach might pay off for you.

Robert Blum

executive
#51

Robert I. Blum): I appreciate you picking up on that. Still, it fits right into how we approach corporate development — some initiatives belong on our plate, while others we're perfectly capable of handling in-house. That said, I wouldn't rule out chances to turn a profit on them later on.

Fady Malik

executive
#52

It's likely that he isn't.

Robert Blum

executive
#53

Jason, are you able to hear us? Operator, it seems we may have lost his connection once more.

Robert Blum

executive
#54

Alright, well, thank you. I appreciate everyone joining us on today’s call. We’re grateful for the ongoing attention you’ve shown toward our efforts. And clearly, I’d say this last quarter offered among the strongest proof so far that we can carry out our plans in sync — both on the R&D side and in corporate development — when it comes to financial engineering and making things operational. That positions us, in our view, for growth and faster progress across our development programs, while we continue to keep solid fiscal discipline, a healthy cash runway, and make sure we can keep building the pipeline. As we head into the back half of the year, we expect results from GALACTIC-HF during the fourth quarter. Naturally, we’re quite hopeful and optimistic, since that stands to bring another major shift for our business. We’re eager to keep you posted as things move forward; and with that, operator, let’s wrap up the call. Thanks so much.

Operator

operator
#55

That wraps up the conference call for today, everyone, and we appreciate your joining us. You're free to disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cytokinetics, Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Cytokinetics, Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cytokinetics, Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.